Interrogating Real-World Case Studies in Validating Computational Models Including De Novo, Generative AI & Machine Learning to Enhance Predictability Power in Biologics Discovery & Development

Welcome to the 10th CDD for Biologics Summit

The landscape of biologics discovery is rapidly evolving, driven by breakthroughs in AI, an influx of high-quality datasets, and regulatory momentum supporting in silico approaches. As industry leaders look to streamline R&D and de-risk development, there is a critical need for cutting-edge tools in modeling, characterization, screening, and developability.

Returning to Boston this fall at this opportune moment, the 10th anniversary of the CDD for Biologics Summit will unite 50+ decision-makers and industry experts from pharma and biotech to share their unfiltered lessons learned from validating and training computational models to streamline novel target validation, enhance biologics design and empower developability predictions.

This is the go-to forum for innovators across pharma and biotech to showcase current pipeline developments that can enable faster, smarter, and more scalable therapeutic design.

Diving into the latest industry applications of computational models, including physics-based, generative AI, and de novo design across multiple large molecules, including peptides, ADCs, bispecific T-cell engagers, multi-specifics, vaccines, and more.

2025 AGENDA LIVE NOW

Expert Speaker Faculty

James Bowman AI Proteins

James Bowman

Senior Investigator & Director - Protein Engineeering

AI Proteins

Jenna Caldwell AstraZeneca

Jenna Caldwell

Associate Principal Scientist

AstraZeneca

Joel Karpiak GSK

Joel Karpiak

Senior Director, Head of Protein Design & Informatics

GlaxoSmithKline

Norbert Furtmann Sanofi

Norbert Furtmann

Group Leader Computational & High-throughput Protein Engineering

Sanofi

Shipra Malhotra Takeda

Shipra Malhotra

Senior Scientist - Biologics, Computational & Machine Learning

Takeda Pharmaceutical

What To Expect

Dive into Lab-in-the-loop AI validation systems for integrating experimental feedback into AI pipelines to refine de novo biologic designs in real-time

Learn how to avoid misleading conclusions by adopting statistically rigorous model performance assessments

Understand the adaptations or de novo design tools needed to predict efficacy, binding, and developability in multi-component biologics

Explore case studies highlighting where early integration of cross-functional perspectives led to more impactful outcomes

Companies in the Room

Sanofi - CDD for Biologics
Visterra - CDD for Biologics
IBM CDD for Biologics
AI Proteins
AstraZeneca
VRG Therapeutics (1)
Eli Lilly & Co
AbbVie
Novartis
Amgen (1)
Takeda
IBM CDD for Biologics
Astellas Pharma
AstraZeneca
Toyota Technological Institute at Chicago
The Francis Crick
A-Alpha Bio Inc.
Tectonic Therapeutic

Hear From Previous Attendees

"I see immense value in attending the Annual CDD for Biologics Summit. This event provides a unique opportunity to stay abreast of cutting-edge computational methods and best practices in biologics research"

Teva Pharmaceuticals

"CDD provides an opportunity to go beyond the hype of AI/ML and discuss with other practitioners in the field the details of what the technology can do today."

Adimab